ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The introduction of BCR-ABL tyrosine kinase inhibitors (TKIs; imatinib, dasatinib, nilotinib, bosutinib and ponatinib) has revolutionised the treatment of chronic myeloid leukaemia (CML).